Compare Alcon AG (ALC) vs VNET Group Inc (VNET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs VNET Group Inc — how do they compare? Alcon AG trades at $66.93 (market cap $32.69B), while VNET Group Inc trades at $8.3 (market cap $2.19B). The key difference: Alcon AG is far larger — about 14.9× VNET Group Inc's market cap, and Alcon AG pays a 0.54% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| ALC | VNET | |
|---|---|---|
Market Cap | $32.69B | $2.19B |
Sector | Health | Technology |
52-Week High | $92.22 | $14.03 |
52-Week Low | $62.02 | $6.97 |
Enterprise Value | $36.28B | $5.32B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
VNET trades at $7.81, down 1.39% today, amid bearish technical signals and recent earnings misses. The stock shows negative profitability with a -21.63% net income margin and -43.21% ROE for 2025, though revenue reached $9.95B. Analyst sentiment remains positive with 62.5% buy ratings, pointing to a 54% upside target. Recent news highlights strategic AI investments and leadership changes, while a class action settlement adds legal overhang.
The outlook is mixed: strong revenue growth and AI demand offer upside, but persistent losses and high debt pose risks. Investors should weigh analyst optimism against fundamental weaknesses and legal uncertainties before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
